- Patent Title: Benzofurans substituted with secondary benzamide as HCV inhibitors
-
Application No.: US15551012Application Date: 2016-02-17
-
Publication No.: US10087167B2Publication Date: 2018-10-02
- Inventor: Tao Wang , Zhiwei Yin , John F. Kadow
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent John F. Levis
- International Application: PCT/US2016/018171 WO 20160217
- International Announcement: WO2016/133963 WO 20160825
- Main IPC: C07D405/10
- IPC: C07D405/10 ; A61P31/14 ; C07D405/12 ; C07D417/14 ; C07D413/14 ; C07D405/14 ; C07D307/84
Abstract:
Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.
Public/Granted literature
- US20180099953A1 BENZOFURANS SUBSTITUTED WITH SECONDARY BENZAMIDE AS HCV INHIBITORS Public/Granted day:2018-04-12
Information query
